Expanded carrier screening and the law of unintended consequences: From cystic fibrosis to fragile X

Genetics in Medicine

Volumn 13, Issue 12, 2011, Pages 996-997

  Grody, Wayne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN;

ALLELE; CYSTIC FIBROSIS; FRAGILE X SYNDROME; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE DETECTION; HUMAN; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; NOTE; PANCREATITIS; PATHOGENICITY; RECURRENT DISEASE; SINUSITIS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC TESTING; GENETICS, MEDICAL; GENETICS, POPULATION; HETEROZYGOTE; HUMANS; MUTATION;

EID: 82955174751     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31823c49a2     Document Type: Note

References (11)

1. Rutkow IM, Lipton JM. Some negative aspects of state health departments' policies related to screening for sickle cell anemia. Am J Public Health 1974;64:217-221.
2. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ; Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee. American College of Medical Genetics. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-154.
3. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004;6:387-391. (Pubitemid 39310514)
4. Grody WW, Cutting GR, Watson MS. The cystic fibrosis mutation "arms race": when less is more. Genet Med 2007;9:739-744. (Pubitemid 350129408)
5. Strom CM, Redman JB, Peng M. The dangers of including nonclassical cystic fibrosis variants in population-based screening panels: p. L997F, further genotype/phenotype correlation data. Genet Med 2011;13:1042-1044.
6. Hantash FM, Goos DM, Crossley B, et al. FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 2011;13:39-45.
7. Nolin SL, Lewis FA, 3rd, Ye LL, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet 1996;59:1252-1261. (Pubitemid 26394116)
8. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-148.
9. Flockhart DA, O'Kane D, Williams MS, et al; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-150.
10. Prior TW; ACMG Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840-842.
11. ACOG Committee on Genetics. ACOG committee opinion No. 432: spinal muscular atrophy. Obstet Gynecol 2009;113:1194-1196.